Kedudukan dalam Saham
#2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$70.50
Disegerakkan terakhir: 2025-11-14
Perubahan (1 tahun)
116.32%
Perdagangan Metsera, Inc. (MTSR)
Harga MTSR dengan permodalan pasaran b
Modal pasaran bagi Metsera, Inc.(MTSR)
Modal Pasaran: $7.33B
Sehingga August 2026, Metsera, Inc. mempunyai modal pasaran sebanyak $7.33B. Ini menjadikan Metsera, Inc. syarikat ke-2738th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Metsera, Inc. dari 2025 hingga 2026
MTSR berbanding dengan 5 teratas yang paling popular stocks
| Harga MTSR |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.152T
|
+70,202.62%
|
|
|
|
|
$4.537T
|
+61,804.95%
|
|
|
|
|
$4.169T
|
+56,777.63%
|
|
|
|
|
$3.642T
|
+49,597.70%
|
|
|
|
|
$2.805T
|
+38,168.52%
|
